Diabetes mellitus, hyperglycaemia and cancer.: Diabetes and cancer

Autor: B. Balkau, Dominique Simon
Přispěvatelé: Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Service de Diabétologie [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de diabétologie [CHU Pitié-Salpétrière]
Jazyk: angličtina
Rok vydání: 2010
Předmět:
Oncology
Male
medicine.medical_specialty
MESH: Diabetes Mellitus
Endocrinology
Diabetes and Metabolism
030209 endocrinology & metabolism
Type 2 diabetes
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Endocrinology
Risk Factors
MESH: Risk Factors
Diabetes mellitus
Internal medicine
Hyperinsulinism
Neoplasms
Internal Medicine
Hyperinsulinemia
Medicine
Humans
cancer
MESH: Neoplasms
Risk factor
MESH: Humans
business.industry
Insulin glargine
facteurs de croissance
Cancer
General Medicine
hyperinsulinémie
medicine.disease
Obesity
MESH: Male
3. Good health
Diabetes Mellitus
Type 2
030220 oncology & carcinogenesis
Hyperglycemia
MESH: Hyperinsulinism
épidémiologie
Female
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
business
MESH: Type 2
MESH: Hyperglycemia
MESH: Female
medicine.drug
diabète
Zdroj: Diabetes and Metabolism
Diabetes and Metabolism, Elsevier Masson, 2010, 36 (3), pp.182-91. ⟨10.1016/j.diabet.2010.04.001⟩
ISSN: 1262-3636
DOI: 10.1016/j.diabet.2010.04.001⟩
Popis: 31 pages; International audience; A moderate increase in cancer risk has been shown in diabetic patients and in individuals with abnormal glucose tolerance, mainly for digestive sites, independently of obesity, with in contrast, a protective effect for prostate cancer. Insulin-resistance with compensatory hyperinsulinemia, and elevated levels of circulating growth factors are usually considered to be the link between cancer and hyperglycaemia, through activated cell proliferation. Treatments inducing elevated plasma insulin seem to increase cancer risk but insulin-sensitizers (metformine, thiazolidinediones) seem to reduce cancer risk. In 2009, there was a controversy on the specific action of glargine insulin to increase cancer risk, from an observational study in Germany, which accumulated a number of methodological pitfalls. There was no confirmation of these results in the three other European studies commissioned by Diabetologia, to validate or to refute the results. The recent interest for cancer in the diabetes community should not distract from appropriate management of diabetic patients to prevent cardiovascular diseases, as the risk for death from macrovascular complications is higher than death from cancer in type 2 diabetic patients. Greater public awareness about healthy lifestyles (diet, physical activity) is needed at the general population level to prevent these two major increasing public health issues, diabetes and cancer, as well as obesity, a risk factor for both of these diseases.
Databáze: OpenAIRE
Externí odkaz: